Imaging Experimental Brain Metastases

作者: Amanda M. Hamilton , Paula J. Foster

DOI: 10.1007/978-94-007-5291-7_5

关键词:

摘要: Studies of the metastatic process and potential cancer therapies have been advanced by use imaging technology that enables noninvasive assessment tumor development over time. Several modalities used to examine brain metastases in preclinical models. Magnetic resonance (MRI) is clinical gold standard for anatomical evaluation metastases. New advances MRI MR spectroscopy (MRS) now enabled physiological characteristics tumors be investigated including permeability, vascularity, cellularity metabolism as well cerebral blood flow volume. can also detect single iron-labeled cells after their initial arrest mouse subsequent development. Nuclear techniques positron emission tomography (PET) photon computed (SPECT) are popular tools classifying monitoring treatment. Brain assessed bio­chemical alterations such glucose use, DNA synthesis, amino acid transport oxygenation state. Optical based on fluorescent or bioluminescent reporters found advantageous burden experimental animals. Fluorescent entities ­further intravital microscopy track monitor relationship between vasculature, cell arrest, early extravasation, perpetuation a perivascular position either angiogenesis vessel co-option. Finally, studies often improved using multiple concurrently, thereby exploiting best features separate acquire multilayered information provide further insights into evolution

参考文章(67)
Wielislaw Papierz, Bożena Goraj, Wiesław Szymczak, Witold Gajewicz, The use of proton MRS in the differential diagnosis of brain tumors and tumor-like processes. Medical Science Monitor. ,vol. 9, ,(2003)
Matthew D. Budde, Eric Gold, E. Kay Jordan, Melissa Smith-Brown, Joseph A. Frank, Phase contrast MRI is an early marker of micrometastatic breast cancer development in the rat brain. NMR in Biomedicine. ,vol. 25, pp. 726- 736 ,(2012) , 10.1002/NBM.1786
Darlene E Jenkins, Yvette S Hornig, Yoko Oei, Joan Dusich, Tony Purchio, Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivodetection of mammary tumors and multiple metastases in immune deficient mice Breast Cancer Research. ,vol. 7, pp. 1- 11 ,(2005) , 10.1186/BCR1026
Robert M. Hoffman, In Vivo Cell Biology of Cancer Cells Visualized with Fluorescent Proteins Current Topics in Developmental Biology. ,vol. 70, pp. 121- 144 ,(2005) , 10.1016/S0070-2153(05)70006-5
Marvin Bergsneider, Paul Mischel, Timothy Cloughesy, Johannes Czernin, Nagichettiar Satyamurthy, Michael E Phelps, Linda Liau, Daniel H S Silverman, Wei Chen, Nirav Kamdar, Imaging Proliferation in Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG The Journal of Nuclear Medicine. ,vol. 46, pp. 945- 952 ,(2005)
I. Chan Chiang, Yu-Ting Kuo, Chia-Ying Lu, Kwok-Wan Yeung, Wei-Chen Lin, Feng-O. Sheu, Gin-Chung Liu, Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings Neuroradiology. ,vol. 46, pp. 619- 627 ,(2004) , 10.1007/S00234-004-1246-7
Alexander A Kortt, Olan Dolezal, Barbara E Power, Peter J Hudson, Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomolecular Engineering. ,vol. 18, pp. 95- 108 ,(2001) , 10.1016/S1389-0344(01)00090-9
Jeff W. M. Bulte, Dara L. Kraitchman, Iron oxide MR contrast agents for molecular and cellular imaging. NMR in Biomedicine. ,vol. 17, pp. 484- 499 ,(2004) , 10.1002/NBM.924
B. Munch-Petersen, L. Cloos, H.K. Jensen, G. Tyrsted, Human thymidine kinase 1. Regulation in normal and malignant cells Advances in Enzyme Regulation. ,vol. 35, pp. 69- 89 ,(1995) , 10.1016/0065-2571(94)00014-T